A detailed history of Citigroup Inc transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 90,402 shares of FDMT stock, worth $760,280. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90,402
Previous 82,810 9.17%
Holding current value
$760,280
Previous $1.74 Million 43.79%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.81 - $27.22 $82,069 - $206,654
7,592 Added 9.17%
90,402 $977,000
Q2 2024

Aug 12, 2024

SELL
$20.93 - $30.01 $1.48 Million - $2.11 Million
-70,474 Reduced 45.98%
82,810 $1.74 Million
Q1 2024

May 10, 2024

BUY
$17.03 - $35.87 $1.91 Million - $4.02 Million
111,976 Added 271.08%
153,284 $4.88 Million
Q4 2023

Feb 09, 2024

SELL
$9.76 - $21.25 $130,696 - $284,558
-13,391 Reduced 24.48%
41,308 $836,000
Q3 2023

Nov 09, 2023

SELL
$12.64 - $19.76 $43,709 - $68,330
-3,458 Reduced 5.95%
54,699 $696,000
Q2 2023

Aug 10, 2023

SELL
$15.16 - $23.26 $811,378 - $1.24 Million
-53,521 Reduced 47.92%
58,157 $1.05 Million
Q1 2023

May 11, 2023

BUY
$15.45 - $23.19 $1.33 Million - $1.99 Million
85,862 Added 332.59%
111,678 $1.92 Million
Q4 2022

Feb 09, 2023

BUY
$6.85 - $25.46 $109,065 - $405,374
15,922 Added 160.93%
25,816 $573,000
Q3 2022

Nov 10, 2022

SELL
$6.96 - $11.48 $16,307 - $26,897
-2,343 Reduced 19.15%
9,894 $80,000
Q2 2022

Aug 10, 2022

SELL
$5.68 - $15.99 $92,913 - $261,564
-16,358 Reduced 57.21%
12,237 $85,000
Q1 2022

May 12, 2022

SELL
$13.16 - $22.64 $718,233 - $1.24 Million
-54,577 Reduced 65.62%
28,595 $432,000
Q4 2021

Feb 10, 2022

BUY
$19.56 - $32.94 $1.57 Million - $2.65 Million
80,369 Added 2867.25%
83,172 $1.83 Million
Q3 2021

Nov 10, 2021

BUY
$22.73 - $36.04 $63,712 - $101,020
2,803 New
2,803 $76,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $272M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.